Pharminent

Fitbit and Dexcom to bring diabetes data to Ionic smartwatch

Dexcom G5 Mobile data will be displayed on Fitbit’s Ionic smartwatch.
The post Fitbit and Dexcom to bring diabetes data to Ionic smartwatch appeared first on Pharmaphorum. https://pharmaphorum.com/news/fitbit-dexcom-ionic-smartwatch/

Filed under: Diabetes

Diabetes drugmakers partner with mobile startups to boost patient engagement

Novo Nordisk and Roche are two examples of drugmakers that are turning to digital-health startups to better engage with patients and mine valuable real-world evidence. http://www.mmm-online.com/technology/diabetes-drugmakers-partner-with-mobile-startups-to-boost-patient-engagement/article/676290/

Filed under: Diabetes

Roche acquires mySugr to form a leading open platform for digital diabetes management

Roche and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH. http://www.roche.com/media/store/releases/med-cor-2017-06-30.htm

Filed under: Diabetes

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

http://www.reuters.com/article/us-novo-nordisk-obesity-semaglutide-idUSKBN19E29X

Filed under: Metabolic

Novo gets US backing for Victoza cardiovascular data

US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes. http://www.pharmatimes.com/news/novo_gets_us_backing_for_victoza_cardiovascular_data_1196325

Filed under: Diabetes, GLP-1

Canvas Paints A Mixed Picture For J&J’s Invokana

https://seekingalpha.com/article/4081122-canvas-paints-mixed-picture-j-and-js-invokana

Filed under: Diabetes, SGLT-2

AstraZeneca taps outcomes deals to boost CV, diabetes meds

Two agreements with Harvard Pilgrim for Brilinta and Bydureon will link drug cost to certain patient outcomes — the most recent examples of value-based deals. http://www.biopharmadive.com/news/astrazeneca-harvard-pilgrim-value-outcomes-brilinta-bydureon/443891/

Filed under: Diabetes

Nokia, Kantar collaborate for diabetes database project

Deal looks to measure impact of ‘Lifestyle Therapy’ on diabetes treatment.
The post Nokia, Kantar collaborate for diabetes database project appeared first on Pharmaphorum. https://pharmaphorum.com/news/nokia-kantar-diabetes-database/

Filed under: Diabetes

Poxel’s diabetes drug Imeglimin succeeds in phase 2b study in Japan

Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan. http://contractresearch.pharmaceutical-business-review.com/news/poxels-diabetes-drug-imeglimin-succeeds-in-phase-2b-study-in-japan-050517-5805963

Filed under: Diabetes

iMedicalApps: Amazon and Merck Think Alexa Can Tackle Diabetes

(MedPage Today) — And a lucky developer who agrees may pocket $150,000 http://www.imedicalapps.com/2017/04/alexa-diabetes-challenge/

Filed under: Diabetes

Endo 2017: Sanofi Presents New Observational Study Data for Toujeo in Type 2 Diabetes

NewsComplementing these observational studies in routine clinical practice and the EDITION program of Phase 3 clinical trials.Topics: Drug Discovery http://www.dddmag.com/news/2017/04/endo-2017-sanofi-presents-new-observational-study-data-toujeo-type-2-diabetes

Filed under: Diabetes

iMedicalApps: Diabetes App Cleared for OTC Use

(MedPage Today) — Helps with self-care in type 2 patients, delivers reports to providers http://www.medpagetoday.com/Blogs/IltifatHusain/64063

Filed under: Diabetes

AstraZeneca study shows cardiovascular benefit to SGLT-2 drugs

The British pharma hopes the results, assessed from real-world data, will help boost use of the newer class of diabetes drugs.  http://www.biopharmadive.com/news/astrazeneca-cvd-real-sglt2-diabetes-farxiga/438425/

Filed under: Diabetes, SGLT-2

FDA Approves Once-Daily QTERN® (Dapagliflozin and Saxagliptin) Tablets for Adults with Type-2 Diabetes

[Business Wire] – AstraZeneca today announced that the US Food and Drug Administration has approved once-daily QTERN® for the treatment of type-2 diabetes. http://finance.yahoo.com/news/fda-approves-once-daily-qtern-071000839.html

Filed under: Diabetes

Diabetes Drug Adherence Rates: How mHealth Makes a Difference

Medicine can’t work when it’s not taken. It sounds simple: “Take your meds as prescribed.” But with multiple doses per day and/or several medications to take, it can quickly become confusing. A combination of rising medication costs, poor self-management, insufficient education, and lack of support have led to poor medication adherence among patients. Research shows […] https://www.pm360online.com/diabetes-drug-adherence-rates-how-mhealth-makes-a-difference/

Filed under: Diabetes

J&J pondering future of diabetes device assets

Three diabetes
care subsidiaries under review as firm forecasts measured 2017 sales http://www.pmlive.com/pharma_news/j_and_j_pondering_future_of_diabetes_device_assets_1185016

Filed under: Diabetes

Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes

CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes. In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin… http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-reports-positive-data-from-phase-2-study-of-ionis-gcgr-rx-in-patients-with-type-2-diabetes-300385182.html

Filed under: Diabetes

Eli Lilly, Boehringer Launch Long-Acting Basal Insulin in U.S.

NewsBASAGLAR will be available by prescription from retail and mail order pharmacies across the U.S. Topics: Drug Pipeline http://www.dddmag.com/news/2016/12/eli-lilly-boehringer-launch-long-acting-basal-insulin-us

Filed under: Diabetes, Insulin

Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil

WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 19, 2016 /PRNewswire/ — Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA)… http://www.prnewswire.com/news-releases/eisai-and-arena-pharmaceuticals-announce-regulatory-approval-of-belviq-lorcaserin-hcl-in-brazil-300381261.html

Filed under: Metabolic

Novo files once-weekly GLP-1 analogue semaglutide

Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes. http://www.pharmatimes.com/news/novo_files_once-weekly_glp-1_analogue_semaglutide_1180190

Filed under: Diabetes, GLP-1

Categories